The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance.
 
Ralynn Brann
No Relationships to Disclose
 
Kevin Michael Kremer
No Relationships to Disclose
 
Matthew Carlson
No Relationships to Disclose
 
Salvatore LoCoco
No Relationships to Disclose
 
Jayanthi Sivasothy Lea
No Relationships to Disclose
 
David Scott Miller
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Alexion Pharmaceuticals; AstraZeneca; Asymmetric Therapeutics; BOSTON BIOMEDICAL RESEARCH INSTITUTE; Clovis Oncology; Eisai; Genentech; GlaxoSmithKline; Guardant Health; Guardant Health; Incyte; Janssen; Janssen Oncology; Karyopharm Therapeutics; Merck Sharp & Dohme (Inst); Myriad Genetic Laboratories; Tarveda Therapeutics; Tesaro
Speakers' Bureau - Clovis Oncology; Genentech
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Akeso Biopharma (Inst); Aprea AB (Inst); AstraZeneca (Inst); Immunogen (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); NVision (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)
 
Jessica Lee
No Relationships to Disclose